Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Vernakalant hydrochloride to treat atrial fibrillation.

Brown RA, Lau YC, Lip GY.

Expert Opin Pharmacother. 2014 Apr;15(6):865-72. doi: 10.1517/14656566.2014.898751. Epub 2014 Mar 11. Review.

PMID:
24617913
2.

Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.

Duggan ST, Scott LJ.

Drugs. 2011 Jan 22;71(2):237-52. doi: 10.2165/10489050-000000000-00000. Review. Erratum in: Drugs. 2011 Feb 12;71(3):381.

PMID:
21275448
3.

Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.

Savelieva I, Graydon R, Camm AJ.

Europace. 2014 Feb;16(2):162-73. doi: 10.1093/europace/eut274. Epub 2013 Oct 9. Review.

PMID:
24108230
4.

Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation.

Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Stevenson R, Gonzalez MD.

Expert Opin Investig Drugs. 2008 May;17(5):805-10. doi: 10.1517/13543784.17.5.805 . Review.

PMID:
18447605
5.

Vernakalant in the management of atrial fibrillation.

Cheng JW.

Ann Pharmacother. 2008 Apr;42(4):533-42. doi: 10.1345/aph.1K542. Epub 2008 Mar 11. Review.

PMID:
18334607
6.

Vernakalant hydrochloride for the treatment of atrial fibrillation.

Kozlowski D, Budrejko S, Lip GY, Mikhailidis DP, Rysz J, Raczak G, Banach M.

Expert Opin Investig Drugs. 2009 Dec;18(12):1929-37. doi: 10.1517/13543780903386246.

PMID:
19938903
7.

Spotlight on intravenous vernakalant in recent-onset atrial fibrillation.

Duggan ST, Scott LJ.

Drugs Aging. 2011 Jun 1;28(6):501-4. doi: 10.2165/11207060-000000000-00000. Review.

PMID:
21639409
8.

Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.

Tsuji Y, Dobrev D.

Vasc Health Risk Manag. 2013;9:165-75. doi: 10.2147/VHRM.S43720. Epub 2013 Apr 23. Review.

9.

Vernakalant: A novel agent for the termination of atrial fibrillation.

Finnin M.

Am J Health Syst Pharm. 2010 Jul 15;67(14):1157-64. doi: 10.2146/ajhp080501. Review.

PMID:
20592320
10.

Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis.

Guerra F, Matassini MV, Scappini L, Urbinati A, Capucci A.

Expert Rev Cardiovasc Ther. 2014 Sep;12(9):1067-75. doi: 10.1586/14779072.2014.943662. Epub 2014 Aug 5. Review.

PMID:
25096598
11.

Conversion of recent onset atrial fibrillation: which drug is faster?

Conde D.

Am J Emerg Med. 2013 Sep;31(9):1410-1. doi: 10.1016/j.ajem.2013.05.039. Epub 2013 Jun 22. No abstract available.

PMID:
23796978
12.

A new antiarrhythmic drug in the treatment of recent-onset atrial fibrillation: vernakalant.

Vizzardi E, Salghetti F, Bonadei I, Gelsomino S, Lorusso R, D'Aloia A, Curnis A.

Cardiovasc Ther. 2013 Oct;31(5):e55-62. doi: 10.1111/1755-5922.12026. Review.

PMID:
23398692
13.

Vernakalant: a new drug to treat patients with acute onset atrial fibrillation.

Tian D, Frishman WH.

Cardiol Rev. 2011 Jan-Feb;19(1):41-4. doi: 10.1097/CRD.0b013e3181f4a6a2.

PMID:
21135602
14.

Flecainide or propafenone vs. vernakalant for conversion of recent-onset atrial fibrillation.

Conde D, Costabel JP, Aragon M, Caro M, Ferro A, Klein A, Trivi M, Giniger A.

Can J Cardiol. 2013 Oct;29(10):1330.e13. doi: 10.1016/j.cjca.2013.01.002. Epub 2013 Mar 5. No abstract available.

PMID:
23465347
15.

Is vernakalant better or not, compared with other treatments for conversion of acute atrial fibrillation?

Conde D.

Int J Cardiol. 2013 Oct 30;169(2):95-6. doi: 10.1016/j.ijcard.2013.08.139. Epub 2013 Sep 5.

PMID:
24071384
16.

Propafenone versus vernakalant for conversion of recent-onset atrial fibrillation.

Conde D, Costabel JP, Aragon M, Lambardi F, Klein A, Corrales Barbosa A, Trivi M, Giniger A.

Cardiovasc Ther. 2013 Dec;31(6):377-80. doi: 10.1111/1755-5922.12036.

PMID:
23683253
17.

[Vernakalant--a new drug for pharmacological conversion of atrial fibrillation].

Hinneburg I.

Med Monatsschr Pharm. 2011 May;34(5):154-8. Review. German.

PMID:
21644373
18.

Recent-onset atrial fibrillation in patients with left ventricular dysfunction: amiodarone or vernakalant?

Conde D, Costabel JP, Alves de Lima A.

Can J Cardiol. 2013 Oct;29(10):1330.e11-1330.e12. doi: 10.1016/j.cjca.2013.02.025. Epub 2013 Apr 29. No abstract available.

PMID:
23639270
19.

Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.

Mao ZL, Wheeler JJ, Clohs L, Beatch GN, Keirns J.

J Clin Pharmacol. 2009 Jan;49(1):17-29. doi: 10.1177/0091270008325148. Epub 2008 Oct 16.

PMID:
18927241
20.

Population pharmacokinetics of vernakalant hydrochloride injection (RSD1235) in patients with atrial fibrillation or atrial flutter.

Mao ZL, Townsend RW, Gao Y, Wheeler JJ, Kastrissios H, Keirns J.

J Clin Pharmacol. 2012 Jul;52(7):1042-53. doi: 10.1177/0091270011408425. Epub 2011 Jun 9.

PMID:
21659624

Supplemental Content

Support Center